IRVINE, California and AMSTERDAM, March 17, 2022–(BUSINESS WIRE)–Agendia, Inc., a commercial company focused on improving decision-making by providing physicians with next-generation diagnostic and information solutions designed to improve outcomes for breast cancer patients worldwide world, today announced the appointment of Elizabeth (Betsy) Hanna, a prominent global sales executive, to executive vice president and chief commercial officer, effective March 15, 2022.
“We are pleased to welcome Betsy as a key member of our management team. She is a globally recognized leader in healthcare and biotechnology with a proven track record of increasing the market value of diagnostic and medical device companies in the United States and around the world,” said Mark Straley, CEO of Agendia. “His extensive experience in developing and executing global growth strategies will benefit Agendia as he will now become an integral part of our management team and will oversee all commercial activities. We look forward to leveraging Betsy’s strategic thinking and responsible leadership to continue to expand our global business strategy. “reach to achieve our goals.”
Most recently, Ms. Hanna served as President and CEO of Clinical Genomics, where she developed and executed go-to-market strategies and advanced the commercialization of liquid biopsy tests for colorectal cancer detection. Prior to her role at Clinical Genomics, Ms. Hanna was President and COO of Origin, Inc., a clinical-stage biotechnology company, where her responsibilities included product development and manufacturing, coordinating clinical trials with the US FDA for the development of strategic plans to support the private financing of a class III medical device.
Ms. Hanna brings a wealth of knowledge from her time in business and management positions at Johnson & Johnson Vision Care and Ortho Clinical Diagnostics. During her tenure at both Johnson & Johnson divisions, she was responsible for global product strategy as well as global and regional plans to increase market share. During her time at Ortho, Ms. Hanna launched two new diagnostic platforms globally and doubled the company’s market growth in Europe. Ms. Hanna is a member of the board of directors for Treace Medical Concepts, Inc., a high-growth orthopedic company. She has a bachelor’s degree in chemical engineering from the University of Illinois and an MBA from Harvard Business School.
“This is an exciting time to be a part of Agendia’s growing business momentum, and I’m particularly excited about the company’s unique approach to bringing meaningful genomic diagnostic solutions to the breast cancer research community,” said Hanna. “I look forward to joining Agendia’s well-established and talented sales team and leading the US and global business in accelerating access to these important trials designed to inform decision-making for women with breast cancer and their physicians.” .
Agendia’s board and management team strive to attract and deploy strong leaders and professionals at all levels to drive company excellence and progress in all areas. The company believes that this commitment will translate into excellence in science, practical and innovative research, and the commercialization of innovative new products. This ensures that breast cancer patients, their families and their doctors have access to the information they need to make the best decisions about their treatment. More information here.
Agendia is a decision-focused, business-focused, mission-driven company providing clinicians with next-generation diagnostic and information solutions that can help improve outcomes for breast cancer patients worldwide. world. The company currently offers two commercially available genomic profiling tests to help surgeons, oncologists and pathologists personalize treatment for women at critical intervention points throughout their disease process.
MammaPrint® is a 70-gene breast cancer recurrence test that, along with other clinicopathological factors, can determine the specific risk of breast cancer recurrence in patients. Flat® is an 80-gene molecular subtyping test that identifies the underlying biology of a given patient’s breast cancer to provide information on the behavior, long-term prognosis, and potential response to systemic therapy of that breast cancer. Together, MammaPrint delivers® and BluePrint® a complete picture of an individual patient’s breast cancer, allowing doctors to objectively select the best treatment plan.
For more information about Agendia’s ongoing trials and studies, visit www.agendia.com.
The source language in which the original text is published is the official and authorized version. Translations will be included for better understanding. Only the version in the language that was originally published is legally valid. Therefore, compare the translations with the original language version of the publication.
View the original version on businesswire.com: https://www.businesswire.com/news/home/20220315005558/en/
ICR Westwicke Healthcare PR